In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 2, 2008, Pages 666-673

  Carcaboso, Ángel M ^a   Chiappetta, Diego A ^a,b   Höcht, Christian ^a   Blake, Mariano G ^a   Boccia, Mariano M ^a,b   Baratti, Carlos M ^a,b   Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Science Research Council ^*  (Argentina)

Author keywords

Gabapentin in vitro release; In vivo pharmacokinetics towards memory studies; Melt molding compression method; Poly(epsilon caprolactone) implants

Indexed keywords

GABAPENTIN; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COMPRESSION METHOD; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; MELT MOLDING METHOD; MEMORY DISORDER; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; TECHNIQUE;

AMINES; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; POLYESTERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 52949128412     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.05.031     Document Type: Article

References (46)

1. Dodrill C.B. Behavioral effects of antiepileptic drugs. Adv. Neurol. 55 (1991) 213-224
2. Brioni J.D., and McGaugh J.L. Post-training administration of GABAergic antagonists enhances retention of aversively motivated tasks. Psychopharmacology (Berl) 96 (1961) 505-510
3. Baratti C.M., and Boccia M.M. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav. Pharmacol. 10 (1999) 731-737
4. Nielson K.A., Czech D.A., and Laubmeier K.K. Chronic administration of propranolol impairs inhibitory avoidance retention in mice. Neurobiol. Learn. Mem. 71 (1999) 248-257
5. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., and Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99 (2000) 17-23
6. Chang B.S., and Lowenstein D.H. Epilepsy. N. Engl. J. Med. 349 (2003) 1257-1266
7. Browne T.R., and Holmes G.L. Handbook of Epilepsy. third ed. (2000), Lippincott Williams & Wilkins, Philadelphia pp. 1-20
8. Vermeulen J., and Aldenkamp A.P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res. 22 (1995) 65-95
9. Shannon H.E., and Love P.L. Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav. 5 (2004) 857-865
10. Shannon H.E., and Love P.L. Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav. 7 (2005) 620-628
11. Carpay J., Aldenkamp A., and van Donselaar C. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 14 (2005) 198-206
12. Meador K.J. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 68 (2006) 63-67
13. Kälviäinen R. Cognitive effects of GABAergic antiepileptic drugs. Electroencephalogr. Clin. Neurophysiol. 103 (1997) 51
14. Dichter M.A., and Brodie M.J. New antiepileptic drugs. N. Eng. J. Med. 13 (1996) 1583-1590
15. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., and Brown J.P. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29 (1998) 233-249
16. Gidal B.E., DeCerce J., Bockbrader H.N., Gonzalez J., Kruger S., Pitterle M.E., Rutecki P., and Ramsay R.E. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31 (1998) 91-99
17. Magnus L. Nonepileptic uses of gabapentin. Epilepsia 40 (1999) S66-S72 discussion S73--4
18. Mack A. Examination of the evidence for off-label use of gabapentin. J. Manag. Care Pharm. 9 (2003) 559-568
19. Acosta G.B., Boccia M.M., and Baratti C.M. Gabapentin, an antiepileptic drug, improves memory storage in mice. Neurosci. Lett. 279 (2000) 173-176
20. Boccia M.M., Acosta G.B., and Baratti C.M. Memory improving actions of gabapentin in mice: possible involvement of central muscarinic cholinergic mechanism. Neurosci. Lett. 311 (2001) 153-156
21. Blake M.G., Boccia M.M., Acosta G.B., and Baratti C.M. Posttraining administration of pentylenetetrazol dissociates gabapentin effects on memory consolidation from that on memory retrieval process in mice. Neurosci. Lett. 368 (2004) 211-215
22. Blake M.G., Boccia M.M., Acosta G.B., Höcht C., and Baratti C.M. Opposite effects of a single versus repeated doses of gabapentin on retention performance of an inhibitory avoidance response in mice. Neurobiol. Learn. Mem. 87 (2007) 192-200
23. D. Perrin, J. English, Polycaprolactone. in: A. Domb, Y. Kost, D. Wiseman, (Eds.), Handbook of biodegradable polymers, Drug targeting and delivery, 1997, pp. 63--77.
24. Kumar N., Ravikumar M.N.V., and Domb A.J. Biodegradable block copolymers. Adv. Drug Deliv. Rev. 53 (2001) 23-44
25. Rathbone M.J., Bunta C.R., Oglea C.R., Burggraafa S., Macmillanb K.L., and Pickering K. Development of an injection molded poly(ε-caprolactone) intravaginal insert for the delivery of progesterone to cattle. J. Control. Release 85 (2002) 61-71
26. Sinha V.R., Bansal K., Kaushik R., Kumria R., and Trehan A. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 278 (2004) 1-23
27. Sun H., Mei L., Song C., Cui X., and Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 27 (2006) 1735-1740
28. Bourges J.L., Bloquel C., Thomas A., Froussart F., Bochot A., Azan F., Gurny R., BenEzra D., and Behar-Cohen F. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Del. Rev. 58 (2006) 1182-1202
29. Dordunoo S.K., Oktaba A.M.C., Hunter W., Min W., Cruz T., and Burt H.M. Release of taxol from poly(ε-caprolactone) pastes: effect of water-soluble additives. J. Control. Release 44 (1997) 87-94
30. Sprockel O.L., Sen M., Shivanand P., and Prapaitrakul W. A melt-extrusion process for manufacturing matrix drug delivery systems. Int. J. Pharm. 155 (1997) 191-199
31. Altpeter H., Bevis M.J., Grijpma D.W., and Feijen J. Non-conventional injection molding of poly(lactide) and poly(ε-caprolactone) intended for orthopedic applications. J. Mater. Sci. Mater. Med. 15 (2004) 175-184
32. Tang P.H., Miles M.V., Glauser T.A., and DeGrauw T. Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection. J. Chromatogr. B. Biomed. Sci. Appl. 727 (1999) 125-129
33. Glien M., Brandt C., Potschka H., and Löscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43 (2002) 350-357
34. Cundy K.C., Annamalai T., Bu L., De Vera J., Estrela J., Luo W., Shirsat P., Torneros A., Yao F., Zou J., Barrett R.W., and Gallop M.A. XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharm. Exp. Therap. 311 (2004) 324-333
35. J. Jacob, B. Carter, D. Magiera, A. Nangia, R. Naji, D. Shohat-Ezer, Z. Shaked, Gastroretentive, bioadhesive drug delivery system for controlled release of gabapentin: pharmacokinetics of gabapentin XL tablets in a fed beagle dog model, Controlled Release Society 33rd Annual Meeting (2006), Vienna, Austria.
36. Chang H.-I., Williamson M.R., Perrie Y., and Coombes A.G.A. Precipitation casting of drug-loaded microporous PCL matrices: Incorporation of progesterone by co-dissolution. J. Control. Release 106 (2005) 263-272
37. Zour E., Lodhi S.A., Nesbitt R.U., Silbering S.B., and Chaturvedi P.R. Stability studies of gabapentin in aqueous solutions. Pharm. Res. 9 (1992) 595-600
38. Volpe D.A., Gupta A., Ciavarella A.B., Faustino P.J., Sayeed V.A., and Khan M.A. Comparison of the stability of split and intact gabapentin tablets. Int. J. Pharm. 350 (2008) 65-69
39. Siegel R.A., Kost J., and Langer R. Mechanistic studies of macromolecular drug release from macroporous polymers. I. Experiments and preliminary theory concerning completeness of drug release. J. Control. Release 8 (1989) 223-236
40. Chang H.-I., Perrie Y., and Coombes A.G.A. Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone. J. Control. Release 110 (2006) 414-421
41. Schliecker G., Schmidt C., Fuchs S., Ehinger A., Sandow J., and Kissel T. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J. Control. Release 94 (2004) 25-37
42. Gunatillake P.A., and Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur. Cells Mater. 5 (2003) 1-16
43. Ratner B.D., and Bryant S.J. Biomaterials: where we have been and where we are going. Annu. Rev. Biomed. Eng. 6 (2004) 41-75
44. Cohn D., Lando G., Sosnik A., Garty S., and Levy A. PEO-PPO-PEO based poly(ether ester urethane)s as degradable thermo-responsive multiblock copolymers. Biomaterials 27 (2006) 1718-1727
45. Fialho S.L., Behar-Cohen F., and Silva-Cunha A. Dexamethasone-loaded poly(ε-caprolactone) intravitreal implants: a pilot study. Eur. J. Pharm. Biopharm. 68 3 (2008) 637-646
46. A.M. Carcaboso, unpublished results.